Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals and Financings

Set Alert for Deals

VC Deals Analysis: July Puts 2017 In A Good Place

The bull run in medtech venture financing activity continued in July, with deal volume going up once again from the previous month. Deal value was also solid, boosted by a number of sizeable rounds that helped lift the total amount of venture dollars raised this year to date to $3.88bn. Barring the possibility of a sudden drought in the VC financing landscape in the next few months, 2017 should be in a good position to beat 2016 in total deal value.

Financing StartUps and SMEs Deals
Advertisement

Latest From Deals

Fresenius Homes In On NxStage

In a move to expand its dialysis empire into the growing home hemodialysis and critical care markets, Fresenius Medical Care has inked a $2bn deal to acquire NxStage Medical.

Renal M & A

M&A Analysis: July M&A Levels Reach Fever Pitch

The summer season is proving to be a hot one for medtech M&A activity, with another busy month of deal-making in July. Twenty-five deals were announced and closed during the month, surpassing June's deal count and making it the month with the highest M&A activity to date.

M & A Deals

Invitae Scores M&A Double Whammy In Reproductive Health Dx

Genetic information specialist Invitae is spreading into the reproductive health market with the proposed acquisition of two genetic testing companies that are focused on this area. The addition of Good Start Genetics and Combinatrix will enable Invitae to gain a foothold in the lucrative perinatal. Prenatal and neonatal testing markets. These deals bring the total number of acquisitions made by Invitae to three this year so far.

M & A Cellular & Genetic

Apollo Endosurgery Inflates Coffers With $36m

Anti-obesity device company Apollo Endosurgery has closed a $36m share offering.

Financing Deals

Apollo Endosurgery Seeks To Raise $31m In Share Sale

Anti-obesity device company Apollo Endosurgery is looking to net around $31m through a sale of 5.7 million shares. The Austin, Texas-based company has seen slow sales in the last couple of years and is planning to use the funds to boost adoption of its endo-bariatric products, which includes the Orbera intragastric balloon and the Lap-Band gastric band which it inherited through acquiring Allergan’s obesity intervention division in 2013.

Financing Deals

Alere Off-Loads Blood Gas Business To Siemens

Alere is selling its Epocal point-of-care blood diagnostics subsidiary to Siemens Healthineers to comply with US antitrust requirements in advance of its pending acquisition by Abbott. Siemens plans to integrate Epocal's epoc blood analysis system with its digital platforms and its existing point-of-care diagnostics.

Commercial Deals

How Does UL Acquisition Of Emergo Consultancy Answer Conflict Of Interest Issues?

The recent acquisition of the Emergo medtech consultancy by Underwriters Laboratory has raised a few eyebrows in the sector. Can a notified body and consultancy co-exist without conflicts of interest?

Europe Medical Device

'Profitable, High-Growth' CellRight Bulks Up Tissue Regenix's Ortho Biz

In acquiring CellRight Technologies, a young but already profitable US company specializing in regenerative bone technologies, UK regenerative medicine firm Tissue Regenix will significantly bulk up its portfolio and accelerate its global commercial growth plans.

M & A Regenerative Medicine

Alere Unloads Its Triage Assets To Quidel

The deal, subject to the completion of Abbott's planned acquisition of Alere, includes the Triage MeterPro cardiovascular and toxicology businesses, as well as the Triage BNP business. These additions will diversify Quidel's portfolio of rapid diagnostic products for critical care settings and give it a stronger presence in the point-of-care market.

In Vitro Diagnostics M & A
See All
UsernamePublicRestriction

Register